Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease.

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalJournal of Viral Hepatitis
Volume19 Suppl 1
Publication statusPublished - Jan 2012

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this